DIA Biosimilars 2013

Caliper Life Sciences

HeartWare names Peter F. McAree as CFO

Monday, July 9, 2012 04:48 PM

HeartWare International, a developer of less invasive, miniaturized circulatory support technologies for treatment of advanced heart failure, has appointed Peter F. McAree as senior vice president, CFO and Treasurer

More... »

Cenduit: Now with Patient Reminders

Caliper, Pfizer launch platform for drug safety

Thursday, November 3, 2011 09:02 AM

Caliper Life Sciences, a provider of tools and services for drug
discovery and life sciences research, has launched a new services
offering based on a panel of cellular assays that measure the effects of
drug candidates on functional activity of proteins called kinases involved
in critical cell-signaling pathways. The technology platform and initial
panel of nine assays were developed in collaboration with Pfizer. The new offering, called In-Cell KinaseScreen, is immediately available for compound screening, profiling, and custom assay development services for CDAS' clients, ranging from academia to pharmaceutical companies.

More... »

CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs